KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Debt to Equity (2017 - 2025)

Aquestive Therapeutics has reported Debt to Equity over the past 9 years, most recently at -$1.11 for Q4 2025.

  • Quarterly results put Debt to Equity at -$1.11 for Q4 2025, down 106.11% from a year ago — trailing twelve months through Dec 2025 was -$1.11 (down 106.11% YoY), and the annual figure for FY2025 was -$1.11, down 106.11%.
  • Debt to Equity for Q4 2025 was -$1.11 at Aquestive Therapeutics, up from -$8.83 in the prior quarter.
  • Over the last five years, Debt to Equity for AQST hit a ceiling of -$0.26 in Q4 2023 and a floor of -$8.83 in Q3 2025.
  • Median Debt to Equity over the past 5 years was -$0.56 (2022), compared with a mean of -$0.99.
  • Biggest five-year swings in Debt to Equity: surged 74.88% in 2021 and later crashed 1181.69% in 2025.
  • Aquestive Therapeutics' Debt to Equity stood at -$0.65 in 2021, then skyrocketed by 32.57% to -$0.44 in 2022, then soared by 41.23% to -$0.26 in 2023, then tumbled by 109.14% to -$0.54 in 2024, then tumbled by 106.11% to -$1.11 in 2025.
  • The last three reported values for Debt to Equity were -$1.11 (Q4 2025), -$8.83 (Q3 2025), and -$0.48 (Q2 2025) per Business Quant data.